Precision BioSciences to Present at Upcoming Virtual Investor Conferences in SeptemberGlobeNewsWire • 09/02/20
Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell TherapyGlobeNewsWire • 08/19/20
Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 08/13/20
Earnings Preview: Precision BioSciences (DTIL) Q2 Earnings Expected to DeclineZacks Investment Research • 08/06/20
Precision BioSciences to Report Second Quarter 2020 Financial Results and Present at Upcoming Investor ConferencesGlobeNewsWire • 08/03/20
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple MyelomaGlobeNewsWire • 06/08/20
Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business UpdateGlobeNewsWire • 05/15/20
Precision BioSciences (DTIL) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 05/08/20
Will Precision BioSciences (DTIL) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 04/27/20
Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human ResourcesGlobeNewsWire • 04/15/20
Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLLGlobeNewsWire • 04/07/20
Precision BioSciences Strengthens Board of Directors with Appointment of Geno GermanoGlobeNewsWire • 03/11/20
Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple MyelomaGlobeNewsWire • 01/13/20
Precision BioSciences Makes Impressive Progress On Mission To Change CAR-T Therapy LandscapeSeeking Alpha • 12/25/19
Why International Flavors & Fragrances, Precision BioSciences, and GameStop Slumped TodayThe Motley Fool • 12/09/19
Precision BioSciences Presents Updated Interim Clinical Data at the ASH Annual Meeting from Relapsed / Refractory NHL and B-ALL Patients Treated at Dose Levels 1 & 2 in the Ongoing Phase 1/2a Clinical Trial of PBCAR0191, a Novel CD19 Targeted Allogeneic CGlobeNewsWire • 12/09/19